IOV-4001 for Melanoma and Lung Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing IOV-4001, a modified immune cell treatment, in adults with advanced melanoma or lung cancer. The treatment aims to improve the ability of the patient's own immune cells to attack cancer by disabling a gene that helps cancer hide.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude participants who require systemic steroid therapy at a dose of 10 mg/day prednisone or equivalent. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment IOV-4001 for melanoma and lung cancer?
Research Team
Iovance Biotherapeutics Study Team
Principal Investigator
Iovance Biotherapeutics
Eligibility Criteria
Adults with advanced melanoma or non-small-cell lung cancer (NSCLC) that can't be surgically removed. They must have had certain prior treatments, good organ function, and no untreated brain metastases or recent live vaccines. Participants need a measurable lesion for the study and agree to use effective birth control.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an infusion of IOV-4001, a genetically modified autologous tumor-infiltrating lymphocytes (TIL) product
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
Treatment Details
Interventions
- IOV-4001 (Monoclonal Antibodies)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Iovance Biotherapeutics, Inc.
Lead Sponsor